iron deficiency
Haematology · 2019–2019
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ferric derisomaltose Treatment of iron deficiency anaemia in adults when oral iron preparations are ineffective or cannot be used, or where there is a clinical need to deliver iron… | Jul 2019 | Deferred | none received |
| ferric derisomaltose Treatment of iron deficiency in adults when oral iron preparations are ineffective or cannot be used, or where there is a clinical need to deliver iron rapidly. | Jul 2019 | Deferred | none received |
What the PBS pays
$15M in government benefit over 2024–25, across 48,870 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ferric derisomaltose | $14.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.